Drugs Containing Excipient (Inactive Ingredient) MAGNESIUM ACETATE

« Back to Dashboard

Generic drugs containing MAGNESIUM ACETATE excipient

Company	Ingredient	NDC	Excipient
SKG Pharma Inc	cabergoline	83085-003	MAGNESIUM ACETATE

Magnesium Acetate Excipient Market Dynamics and Financial Trajectory

Last updated: August 10, 2026

Magnesium acetate is a low-volume, multi-industry chemical with limited public evidence of a separately reported pharmaceutical-excipient market. Pharmaceutical demand is driven by formulation utility, specification control, regional supply security, and cost rather than by branded-drug exclusivity. The largest commercial influences are likely outside pharmaceuticals, particularly deicing, industrial processing, laboratory reagents, and water-treatment applications.

The pharmaceutical opportunity is defensible in specialized formulations but has limited pricing power. No standalone blockbuster product, Orange Book patent estate, biosimilar exposure, or material Paragraph IV litigation is associated with magnesium acetate as an excipient.

What is magnesium acetate and how is it used in pharmaceutical formulations?

Magnesium acetate is the magnesium salt of acetic acid. It is sold in anhydrous and hydrated forms, most commonly magnesium acetate tetrahydrate. The anhydrous compound is commonly identified by CAS Registry Number 142-72-3, while magnesium acetate tetrahydrate is commonly identified by CAS Registry Number 16674-78-5.[1]

In pharmaceutical manufacturing, magnesium acetate can be relevant as:

• A magnesium source in oral or parenteral formulations, subject to route-specific safety and quality requirements.
• An electrolyte or mineral component.
• A buffering or pH-adjusting agent in selected formulations.
• A processing aid where magnesium and acetate ions are compatible with the formulation.
• A laboratory or manufacturing reagent rather than a finished-product excipient.

The practical role depends on grade, hydration state, elemental magnesium content, residual solvents, heavy-metal limits, microbial specifications, particle-size distribution, and compatibility with the active pharmaceutical ingredient.

Magnesium acetate should not be treated as interchangeable with magnesium stearate. Magnesium stearate is a hydrophobic tablet lubricant used extensively in solid oral dosage forms. Magnesium acetate is an ionic, water-soluble salt with a different chemical function and different compatibility profile.

How large is the magnesium acetate pharmaceutical-excipient market?

No widely cited public source reports a standalone global revenue figure for pharmaceutical-grade magnesium acetate. Market reports that aggregate "magnesium acetate" generally combine pharmaceutical, industrial, deicing, laboratory, and other applications. Those figures cannot be used as a reliable estimate of pharmaceutical-excipient revenue.

The pharmaceutical segment is likely small relative to total magnesium acetate consumption for three reasons:

1. Magnesium acetate has broad industrial uses that can exceed pharmaceutical demand.
2. Many pharmaceutical formulations use alternative magnesium salts, including magnesium oxide, magnesium hydroxide, magnesium citrate, magnesium chloride, and magnesium sulfate.
3. Pharmaceutical buyers often procure the material as part of a broader excipient or mineral-salt portfolio rather than through a dedicated magnesium acetate supply contract.

The market is therefore best analyzed as a specialty excipient niche within a larger commodity-to-specialty chemical market.

Indicative market structure

Market layer	Commercial position	Main buying criteria
Industrial magnesium acetate	Largest addressable pool in many regions	Price, purity, logistics, moisture control
Laboratory and reagent grade	Higher unit value, smaller volumes	Certificate of analysis, trace metals, lot consistency
Pharmaceutical grade	Smaller volume, higher qualification burden	GMP controls, pharmacopeial compliance, auditability
Custom formulation supply	Smallest volume, highest switching cost	Regulatory support, technical service, supply continuity

The financial profile is closer to a qualified specialty raw material than to a protected pharmaceutical product.

What drives magnesium acetate excipient demand?

Demand is tied to pharmaceutical production volumes, electrolyte and mineral products, formulation development, and regional manufacturing capacity.

Oral dosage forms

Oral liquid, powder, sachet, and tablet products are the most plausible pharmaceutical applications. Magnesium acetate can be used where the formulation requires a soluble magnesium source or acetate counterion. Demand depends on elemental-magnesium dosing, taste, hygroscopicity, dissolution behavior, and gastrointestinal tolerability.

Solid-dose use is limited by the availability of competing magnesium salts and by the fact that magnesium acetate is not a standard lubricant substitute for magnesium stearate.

Parenteral and sterile products

Sterile use carries a higher qualification burden. Suppliers must demonstrate control of endotoxins, bioburden, particulate matter, elemental impurities, and manufacturing-process consistency. A supplier that sells only technical or food grade material cannot assume that the product is suitable for injectable use.

Nutraceutical and medical-nutrition products

Magnesium acetate may compete with more established magnesium ingredients in dietary supplements and medical nutrition. Price, elemental magnesium percentage, sensory profile, absorption claims, and local regulatory classification influence adoption.

Nonpharmaceutical demand

Industrial applications can materially affect capacity, pricing, and lead times. Deicing and chemical-processing demand can create seasonal or regional pressure even when pharmaceutical consumption remains stable. A pharmaceutical buyer may therefore face supply risk caused by nonpharmaceutical markets rather than by growth in drug manufacturing.

What are the main financial drivers for magnesium acetate suppliers?

Supplier economics are determined by raw-material costs, crystallization or drying requirements, quality systems, packaging, and customer qualification.

Raw materials and conversion costs

The basic synthesis uses magnesium-containing feedstock and acetic acid or acetate intermediates. Cost exposure depends on:

• Magnesium source pricing.
• Acetic acid pricing.
• Energy used for reaction, concentration, crystallization, and drying.
• Water removal for anhydrous or controlled-hydration grades.
• Waste treatment and process yield.
• Packaging and freight.

Hydrated and anhydrous products should be modeled separately. A change in water content changes apparent product weight, elemental magnesium concentration, storage behavior, and freight economics.

Quality-system costs

Pharmaceutical-grade production requires more than chemical purity. Suppliers may need:

• GMP-aligned manufacturing controls.
• Validated analytical methods.
• Traceability from raw materials to finished lots.
• Change-control procedures.
• Supplier qualification files.
• Stability and retest data.
• Auditable deviation and complaint systems.
• Control of elemental impurities under ICH Q3D principles.[2]

These costs create a gap between technical-grade pricing and pharmaceutical-grade pricing. The gap can support higher gross margins, but only if the supplier has enough qualified demand to absorb the compliance cost.

Packaging and logistics

Magnesium acetate may be moisture-sensitive or affected by hydration-state changes. Packaging selection, warehouse humidity, transit time, and regional climate can affect specification compliance. Small-volume pharmaceutical orders also carry higher per-kilogram packaging and documentation costs than bulk industrial shipments.

What is the financial trajectory for the magnesium acetate excipient market?

The base-case trajectory is low-to-moderate growth in pharmaceutical demand, with revenue growth potentially exceeding volume growth where buyers migrate from general-purpose material to qualified pharmaceutical grades.

Scenario	Volume trajectory	Pricing trajectory	Financial result
Base case	Low single-digit growth	Stable to modest increase	Gradual revenue expansion
Upside case	Higher growth in electrolyte, nutrition, or specialty formulations	Premium for qualified supply	Above-market specialty-chemical growth
Downside case	Flat or declining use in new formulations	Price competition from alternative salts	Margin compression
Supply-disruption case	Temporary shortage or qualification bottleneck	Short-term price increase	Higher revenue but unstable customer retention

The upside case does not depend on patent protection. It depends on formulation adoption, dual-source qualification, and reliable regulatory documentation.

The downside case is more probable when magnesium acetate is selected for a formulation without a strong performance advantage over magnesium citrate, magnesium chloride, magnesium oxide, or another acetate-compatible salt.

What patents protect magnesium acetate formulations and manufacturing methods?

Magnesium acetate itself is an established chemical entity and is not generally expected to have meaningful composition-of-matter exclusivity. Patent value can arise from a specific formulation, manufacturing process, particle-size profile, hydration state, combination product, or therapeutic use.

Relevant patent categories include:

• Pharmaceutical compositions containing magnesium acetate and an active ingredient.
• Controlled-release formulations.
• Taste-masked oral liquids or powders.
• Stable aqueous solutions.
• Specific crystalline or hydrated forms.
• Manufacturing processes that improve purity or yield.
• Combination electrolyte formulations.
• Medical-use claims tied to a particular disease or dosing regimen.

A patent search should distinguish claims directed to magnesium acetate from claims that merely list it among hundreds of possible excipients. Broad Markush disclosure does not necessarily create a commercially meaningful barrier.

Patent strength is strongest when a patent claims a narrow, reproducible technical feature that competitors must use to achieve the same product performance. It is weaker when magnesium acetate is an optional excipient in a broad formulation list.

When does magnesium acetate lose exclusivity, and what is the Orange Book status?

Magnesium acetate does not have a meaningful product-level exclusivity timeline comparable to a new molecular entity. The material is an established chemical and is available from multiple chemical and specialty-material suppliers.

The FDA Orange Book is organized around approved drug products and listed patents, not standalone excipients.[3] Magnesium acetate should not be expected to have an independent Orange Book listing. Any Orange Book patent exposure would attach to a finished drug product that uses magnesium acetate, not to the excipient as a commodity.

FDA inactive-ingredient status must be assessed at the specific route, dosage form, and maximum daily exposure. Inclusion in the FDA Inactive Ingredient Database does not establish universal suitability for every formulation or route.[4]

Are there Paragraph IV challenges or generic-entry risks for magnesium acetate products?

There is no identifiable generic-entry risk directed at magnesium acetate as an excipient. Paragraph IV litigation applies to patents listed for approved reference drug products under the abbreviated new drug application pathway. An excipient supplier is not normally the target of a Paragraph IV challenge.

Generic-entry risk can arise indirectly where:

• A branded drug uses a formulation patent that names magnesium acetate.
• An ANDA applicant challenges a drug-product patent involving magnesium acetate.
• A supplier change triggers a drug manufacturer’s regulatory supplement or comparability work.
• A formulation owner uses a proprietary grade or manufacturing process.

The principal commercial risk is supplier substitution, not loss of exclusivity.

What FDA and regulatory requirements apply to pharmaceutical-grade magnesium acetate?

Regulatory acceptability depends on the finished product and the supplier’s quality documentation. Key controls include:

• Identity and assay.
• Water content and hydration state.
• Acetate and elemental magnesium content.
• Residual solvents.
• Elemental impurities.
• Microbial quality.
• Particle-size distribution where relevant.
• Packaging compatibility.
• Stability and retest period.
• Change-control notification.

The supplier should provide a current certificate of analysis and evidence supporting the declared grade. A pharmaceutical manufacturer remains responsible for demonstrating that the excipient is suitable for its intended use.

Pharmacopeial status should be confirmed against the current edition of the applicable compendium. A supplier’s reference to "USP," "NF," "Ph. Eur.," or another standard should be checked against the exact product form, monograph requirements, and certificate language.[5]

Which companies compete in magnesium acetate supply?

Competition is fragmented. It includes global chemical distributors, laboratory-reagent manufacturers, specialty inorganic-salt producers, and regional pharmaceutical-excipient suppliers. Supplier identity can change by geography and product form, and catalog availability does not prove commercial pharmaceutical qualification.

The competitive factors are:

• Pharmaceutical manufacturing site and inspection history.
• Availability of anhydrous and hydrated grades.
• Batch-size flexibility.
• Documentation quality.
• Regional inventory.
• Dual-source support.
• Change notification.
• Ability to supply under quality agreements.
• Control of moisture and particle-size specifications.

For buyers, the most important distinction is between catalog availability and qualified commercial supply. A product listed online may be research grade, reagent grade, or technical grade and may not support a regulated drug application.

What licensing deals and litigation affect magnesium acetate?

No major licensing transaction is associated specifically with magnesium acetate as a pharmaceutical excipient. Licensing is more likely to involve a finished drug, delivery technology, or formulation platform that includes magnesium acetate as one component.

No material, widely reported patent litigation appears to be directed specifically at magnesium acetate supply as an excipient. Litigation risk is product-specific and should be evaluated through the finished-drug patent landscape, supplier contracts, and formulation patents.

Contract terms remain commercially important. A buyer should examine exclusivity, geographic supply rights, minimum purchase commitments, quality deviations, change notification, force majeure, and termination rights. These provisions can affect supply continuity more than patent rights.

How does magnesium acetate compare with competing magnesium salts?

Material	Common commercial role	Main advantage	Main limitation
Magnesium acetate	Soluble magnesium or acetate source	Water solubility and formulation flexibility	Limited standardization across applications
Magnesium citrate	Oral magnesium and nutrition	Established consumer and pharmaceutical use	Taste, gastrointestinal effects, formulation constraints
Magnesium chloride	Electrolyte and topical applications	High solubility	Corrosiveness and taste
Magnesium sulfate	Injectable and medical uses	Established clinical use	Different indication and formulation profile
Magnesium oxide	Tablets and supplements	High elemental magnesium content, low cost	Low water solubility
Magnesium stearate	Tablet lubricant	Strong processing history	Not a substitute for soluble magnesium acetate

Magnesium acetate is commercially attractive when its solubility, ion profile, or compatibility produces a measurable formulation benefit. It is less attractive when the only selection criterion is magnesium content or lowest cost.

What geographic coverage and manufacturing barriers matter?

The primary geographic risks are concentration of qualified production, dependence on imported raw materials, port and freight disruption, and local regulatory requirements.

Manufacturing barriers are moderate rather than extreme. The chemistry is not inherently difficult, but pharmaceutical-grade execution requires consistent hydration control, impurity management, validated testing, and reliable documentation. The qualification cycle can be longer than the technical complexity would suggest.

A second-source strategy is commercially justified for products with high annual volume, narrow release specifications, sterile use, or limited reformulation flexibility. Dual sourcing is more difficult when the two suppliers produce different hydration states or use different impurity-control profiles.

Key Takeaways

• Magnesium acetate is a specialty pharmaceutical excipient within a broader industrial chemical market.
• Public data do not support a reliable standalone pharmaceutical-market revenue estimate.
• Pharmaceutical demand is likely small relative to total magnesium acetate demand.
• Revenue growth depends on qualified-grade adoption, electrolyte and nutrition formulations, and supply reliability.
• The material has no meaningful standalone Orange Book, Paragraph IV, biosimilar, or product exclusivity profile.
• Patent value resides in specific formulations, manufacturing methods, hydration states, and therapeutic uses.
• The principal commercial risks are substitution by other magnesium salts, supplier qualification delays, quality-system costs, and nonpharmaceutical demand shocks.
• Pharmaceutical-grade suppliers can earn a premium, but the market remains price-sensitive and technically substitutable.

FAQs

Is magnesium acetate an FDA-approved excipient?

Magnesium acetate should be assessed through the FDA Inactive Ingredient Database and the applicable finished-product review. Acceptance depends on dosage form, route, exposure, grade, and formulation use rather than on a universal excipient approval.

Is magnesium acetate interchangeable with magnesium stearate?

No. Magnesium acetate is a soluble magnesium salt, while magnesium stearate is primarily a tablet lubricant. Their chemical functions and formulation behavior differ substantially.

Does magnesium acetate have a USP-NF monograph?

The applicable current compendial status must be confirmed against the current USP-NF edition and the exact anhydrous or hydrated product form. Supplier marketing language alone is not sufficient evidence of monograph compliance.

Can a pharmaceutical company switch magnesium acetate suppliers without FDA notification?

A supplier change can require internal qualification, stability assessment, quality documentation, and regulatory action depending on the product, filing, and material specifications. The regulatory impact is determined by the finished drug application.

What is the biggest investment risk in magnesium acetate supply?

The main risk is limited pharmaceutical differentiation. Buyers can often evaluate alternative magnesium salts or qualify another supplier, which constrains long-term pricing power unless the material is embedded in a technically difficult formulation.

References

1. National Center for Biotechnology Information. (n.d.). PubChem compound summary: Magnesium acetate. PubChem. https://pubchem.ncbi.nlm.nih.gov/
2. International Council for Harmonisation. (2014). ICH Q3D(R2): Guideline for elemental impurities. https://www.ich.org/
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
4. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveingredientdatabase
5. United States Pharmacopeial Convention. (2025). United States Pharmacopeia and National Formulary. USP.